2022 World Conference on Lung Cancer (ePosters)-EP11.04-001. Cytokeratin 5-Positive Pulmonary Adenocarcinoma: A Study with Resected Specimens

EP11.04-001. Cytokeratin 5-Positive Pulmonary Adenocarcinoma: A Study with Resected Specimens

Pdf Summary

The study aimed to evaluate the frequency and clinicopathological characteristics of CK5-positive pulmonary adenocarcinoma (ADC). The specimens were obtained from resected lung ADC patients and were histologically reviewed by two pathologists. The ADC cases were classified into subtypes according to the World Health Organization (WHO) criteria. The study used different methods to detect genetic alterations in the ADC cases.<br /><br />The results showed that CK5-positive ADCs were associated with higher stage, histological high-grade components, vascular invasion, mucinous differentiation, spread through airspace (STAS), TTF-1 negativity, EGFR wild-type, and ROS1 rearrangement. Over half of the CK5-positive ADCs had mucinous differentiation. Patients with CK5-positive ADCs had worse disease-free survival (DFS) and overall survival (OS) rates compared to those with CK5-negative ADCs. The multivariate analysis revealed that CK5 was an independent recurrent and poor prognostic factor.<br /><br />These findings suggest that CK5-positive ADC is a clinically aggressive tumor with a high-grade morphology and mucinous differentiation. The study highlights the importance of evaluating CK5 expression in pulmonary ADC and considering it as a prognostic marker.<br /><br />The study provides valuable insights into the clinicopathological characteristics and prognosis of CK5-positive ADC. Further research is needed to understand the molecular mechanisms and potential therapeutic implications of CK5-positive ADC.

Asset Subtitle

Akihiko Yoshizawa

Meta Tag

Speaker Akihiko Yoshizawa

Topic Pathology - Tumour Diagnostics

Keywords

CK5-positive pulmonary adenocarcinoma

clinicopathological characteristics

genetic alterations

mucinous differentiation

TTF-1 negativity

ROS1 rearrangement

disease-free survival

aggressive tumor

prognostic marker

therapeutic implications